Data Insights

Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma by ICell Gene Therapeutics for Multiple Myeloma (Kahler Disease): Likelihood of Approval

Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma is under clinical development by ICell Gene Therapeutics...

Data Insights

ICG-122 by ICell Gene Therapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Lupus Nephritis: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Lupus Nephritis

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Systemic Lupus Erythematosus

Data Insights

Gene Therapy to Target CD33 and CLL1 for Oncology by ICell Gene Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Gene Therapy to Target CD33 and CLL1 for Oncology is under clinical development by ICell Gene Therapeutics and currently in...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD33 And CLL1 For Oncology in Relapsed Acute Myeloid Leukemia

Data Insights

Gene Therapy to Target CD33 and CLL1 for Oncology by ICell Gene Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Gene Therapy to Target CD33 and CLL1 for Oncology is under clinical development by ICell Gene Therapeutics and currently in...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD33 And CLL1 For Oncology in Refractory Acute Myeloid Leukemia

Data Insights

ICG-122 by ICell Gene Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Chronic Myelomonocytic Leukemia (CMML)

Data Insights

ICG-122 by ICell Gene Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

ICG-122 by ICell Gene Therapeutics for Sezary Syndrome: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Sezary Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Sezary Syndrome

Data Insights

Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma by ICell Gene Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval

Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma is under clinical development by ICell Gene Therapeutics...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target BCMA And CD38 For Relapsed And RefractoryMultiple Myeloma in Relapsed Multiple Myeloma

Data Insights

ICG-122 by ICell Gene Therapeutics for Cutaneous T-Cell Lymphoma: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Cutaneous T-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Cutaneous T-Cell Lymphoma

Data Insights

ICG-122 by ICell Gene Therapeutics for T-Cell Leukemia: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Leukemia

Data Insights

ICG-122 by ICell Gene Therapeutics for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)

Data Insights

ICG-136 by ICell Gene Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

ICG-136 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-136 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

ICG-122 by ICell Gene Therapeutics for T-Cell Lymphomas: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Lymphomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Lymphomas

Data Insights

Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma by ICell Gene Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval

Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma is under clinical development by ICell Gene Therapeutics...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target BCMA And CD38 For Relapsed And RefractoryMultiple Myeloma in Refractory Multiple Myeloma

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Relapsed Multiple Myeloma

Data Insights

Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus by ICell Gene Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus is under clinical development by ICell...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target BCMA And CD19 For Blood Cancers And Systemic Lupus Erythematosus in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus by ICell Gene Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval

Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus is under clinical development by ICell...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target BCMA And CD19 For Blood Cancers And Systemic Lupus Erythematosus in Systemic Lupus Erythematosus